Anorexia News and Research

RSS

Study challenges notion of fear of weight gain in patients with anorexia nervosa

A study from Inserm, Paris Descartes University and Sainte Anne Hospital suggests that anorexia nervosa might not be explained by fear of gaining weight, but by the pleasure of losing it... and that the phenomenon might be genetically influenced.

8 Jun 2016

FDA approves blood-based cobas EGFR Mutation Test v2 for NSCLC patients

The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients.

2 Jun 2016

Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial.

23 May 2016

Women suffering from anorexia nervosa or obesity may respond differently to taste

Researchers at the University of Colorado Anschutz Medical Campus have discovered that women suffering from anorexia nervosa and those who are obese respond differently to taste, a finding that could lead to new treatments for the eating disorders.

17 May 2016

Transcranial direct current stimulation proves effective for binge-eating disorder

Transcranial direct current stimulation, or tDCS, has proved effective for binge-eating disorder for the first time, according to researchers at the University of Alabama at Birmingham.

10 May 2016

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.

4 May 2016

Combination of genetic, environmental risk factors can trigger fatal eating disorder in humans

In a new study, researchers from Columbia University Medical Center described a new mouse model featuring a combination of genetic and environmental risk factors that can trigger the compulsive restriction of food intake seen in patients with anorexia nervosa. The findings may help to identify new prevention and treatment strategies for the eating disorder in humans.

12 Apr 2016

Radiation therapy plus PCV chemotherapy improves survival of low-grade glioma patients

Patients with a low-grade type of brain tumor called glioma who received radiation therapy plus a chemotherapy regimen, including procarbazine, lomustine and vincristine (PCV), experienced a longer progression-free survival and overall survival than patients who received radiation therapy alone, according to the results of the clinical trial, Radiation Therapy Oncology Group 9802 published in the April 7 issue of the New England Journal of Medicine.

7 Apr 2016

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe.

15 Mar 2016

Helsinn, Mundipharma sign distribution, license and supply agreements for anamorelin

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announce that they have entered into distribution, license and supply agreements with Mundipharma and its network of independent associated companies granting exclusive rights to anamorelin in Norway, Finland, Sweden, Denmark and Iceland.

16 Feb 2016

Mortality risk higher in people with eating disorders

Results from a newly published study indicate that individuals with eating disorders are at increased risk of death compared to the general population. Investigators found that individuals with anorexia nervosa (AN) had a five times higher mortality rate than their same age peers.

22 Jan 2016

Turing Pharmaceuticals emphasizes continued availability of Daraprim

Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases and conditions, today emphasizes the continued availability of Daraprim and cautions healthcare providers of proposed alternatives to Daraprim.

20 Dec 2015

Holidays can be a tough time for people with eating disorders

With food everywhere you look, difficult relatives and pressure to create perfect memories, the holidays can be a tough time for those who struggle with eating disorders.

13 Dec 2015

Helsinn one step closer to bringing anamorelin HCI to market for treatment of anorexia, cachexia in NSCLC patients

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announced that the European Medicines Agency accepted for review, the marketing authorization application (MAA) for anamorelin HCI, a novel, orally active selective ghrelin receptor agonist under development for the treatment of anorexia, cachexia, or unintended weight loss in non-small cell lung cancer (NSCLC) patients.

30 Nov 2015

Bullies and victims at risk for eating disorders

Being bullied in childhood has been associated with increased risk for anxiety, depression and even eating disorders. But according to new research, it's not only the victims who could be at risk psychologically, but also the bullies themselves.

17 Nov 2015

Research findings open up new avenues for treatment of people with anorexia nervosa

When people with anorexia nervosa decide what to eat, they engage a part of the brain associated with habitual behavior. This finding by researchers at Columbia University Medical Center, New York State Psychiatric Institute, the Mortimer B. Zuckerman Mind Brain Behavior Institute, and New York University was published today in Nature Neuroscience.

13 Oct 2015

UNC researchers find association between gut microbiota and anorexia nervosa

Researchers at the UNC School of Medicine found that people with anorexia nervosa have very different microbial communities residing inside their guts compared to healthy individuals and that this bacterial imbalance is associated with some of the psychological symptoms related to the eating disorder.

5 Oct 2015

Allergan settles patent litigation with Amneal related to NAMENDA XR extended release capsules

Allergan plc, today announced that its subsidiaries Forest Laboratories, LLC and Forest Laboratories Holdings, Ltd., along with Adamas Pharmaceuticals, Inc., have entered into a settlement agreement with Amneal Pharmaceuticals LLC and related companies and subsidiaries.

10 Sep 2015

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Helsinn, the Swiss Group focused on building quality cancer care, and BIAL - Portela & Ca. S.A., one of the largest Iberian pharmaceutical companies, today announce that they have entered into an agreement for the exclusive distribution and licence rights to Anamorelin in Spain, Portugal, Angola and Mozambique.

8 Sep 2015

New study may lead to effective treatment to prevent common chemotherapy side effects in cancer patients

Annually, hundreds of thousands of patients battling cancer undergo chemotherapy, which often results in poorly tolerated side effects such as nausea, vomiting, and loss of the desire to eat.

28 Aug 2015